Tan Mengshan, Li Jieqiong, Ma Fangchen, Zhang Xing, Zhao Qingfei, Cao Xipeng
Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Department of Neurology, Qingdao Municipal Hospital, Weifang Medical University, Qingdao, China.
Front Neurosci. 2019 Feb 14;13:116. doi: 10.3389/fnins.2019.00116. eCollection 2019.
Next-generation sequencing studies have reported that rare variants in were associated with increased risk of late-onset Alzheimer's disease (LOAD) in European cohorts. The association has been replicated in a Han Chinese cohort, two rare variants p.I163M in exon7 and p.R356H in exon11 of were found to be associated with LOAD risk. Whether these variants have deleterious effects on protein function, and the underlying mechanisms by which they influence LOAD pathogenesis are unknown. Our results are the first to validate the hypothesis that these variants could lead to reduced PLD3 activity and affect amyloid-β levels in cellular model of AD, possibly via autophagy-dependent mTOR signaling pathway, indicating that PLD3 may represent a new therapeutic target for AD.
下一代测序研究报告称,在欧洲人群队列中,[基因名称]的罕见变异与晚发型阿尔茨海默病(LOAD)风险增加相关。该关联已在一个汉族人群队列中得到重复验证,在[基因名称]的外显子7中的两个罕见变异p.I163M和外显子11中的p.R356H被发现与LOAD风险相关。这些变异是否对蛋白质功能具有有害影响,以及它们影响LOAD发病机制的潜在机制尚不清楚。我们的结果首次验证了以下假设:这些变异可能导致PLD3活性降低,并在AD细胞模型中影响淀粉样β蛋白水平,可能是通过自噬依赖性的mTOR信号通路,这表明PLD3可能代表AD的一个新的治疗靶点。